During Monday’s Current trade, Shares of Baker Hughes Incorporated (NYSE:BHI), gain 1.22% to $56.40.
Baker Hughes Incorporated (BHI) Chairman and Chief Executive Officer Martin S. Craighead declared recently that the Baker Hughes Board of Directors declared the regular quarterly cash dividend of $0.17 per share of common stock payable September 23, 2015 to holders of record on September 2, 2015.
Baker Hughes Incorporated supplies oilfield services, products, technology, and systems to the oil and natural gas industry worldwide. The company offers drilling and evaluation products and services, which comprise drill bits for performance drilling, hole enlargement, and coring; conventional and rotary steerable systems used to drill wells; measurement-while-drilling and logging-while-drilling systems to perform reservoir navigation services; drilling optimization services; tools for coil tubing drilling and wellbore re-entry systems; coring drilling systems; surface logging; emulsion and water-based drilling fluids systems; reservoir drill-in fluids; and fluids environmental services.
Shares of Prospect Capital Corporation (NASDAQ:PSEC), inclined 0.63% to $7.18, during its current trading session.
Prospect Capital Corporation (PSEC) declared that their July 9 presentation from Grier Eliasek , President and Chief Operating Officer, is now accessible for on-demand viewing at VirtualInvestorConferences.com.
Prospect Capital Corporation is a business development company. It specializes in middle market, mature, mezzanine finance, later stage, emerging growth, buyouts, recapitalizations, turnaround, growth capital, development, subordinated debt tranches of collateralized loan obligations, cash flow term loans, and bridge transactions. It also makes real estate investments particularly in multi-family residential real estate asset class. The fund makes secured debt, senior debt, unitranche debt, first-lien and second lien, private debt, mezzanine debt, and equity investments in private and microcap public businesses. It typically invests across all industry sectors, with a particular expertise in the energy and industrial sectors.
Sequenom, Inc. (NASDAQ:SQNM), during its Monday’s current trading session gained 1.75% to $2.32.
Sequenom, Inc. (SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, stated total revenues of $32.8 million for the second quarter of 2015, a decrease of 18% contrast to revenues of $39.8 million for the second quarter of 2014. Revenues for the second quarter of 2014 comprised of about $6.1 million of incremental “catch-up” payments from payors for services performed in preceding periods, in addition to the incremental change for the conversion from cash to accrual accounting for certain payors. No noteworthycatch-up collections were received in the second quarter of 2015, as the timeliness of collections has improved with additional payor contracts. Sequenom now has coverage for 172 million commercial lives and 40 million lives under Medicaid programs. The second quarter of 2015 had lower diagnostic services revenues contrast to the second quarter of 2014 by about $3 million, associated with the conversion of a referring laboratory partner to a patent pool licensee.
License revenues raised to $1.9 million for the second quarter of 2015, contrast to $0.4 million for the second quarter of 2014, reflecting the enhance in test fees under the Pooled Patents Agreement that was signed in December 2014.
The MaterniT GENOME test builds upon the industry leading microdeletion performance demonstrated by Sequenom Laboratories with the MaterniT21 PLUS laboratory-developed test, which was recently highlighted in an article by Hume JH, et al, published in the peer-reviewed journal Prenatal Diagnosis. Data supporting the validation of the MaterniT GENOME test will be presented at the 19th International Conference on Prenatal Diagnosis and Treatment (sponsored by the International Society of Prenatal Diagnosis and Therapy - ISPD) in Washington D.C., taking place July 12-15, 2015. The MaterniT GENOME test will be accessible to physicians later this quarter.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
Finally, Dana Holding Corporation (NYSE:DAN), gained 1.50%, to $18.96.
Dana Holding Corporation (DAN) declared that its board of directors has declared a dividend on its common stock.
The board declared a quarterly dividend of $0.06 per share, payable Sept. 11, 2015, to holders of Dana common stock as of Aug. 21.
Dana Holding Corporation manufactures and sells driveline, sealing, and thermal-administration products for vehicle manufacturers in North America, Europe, South America, and the Asia Pacific. The company operates in four segments: Light Vehicle Driveline Technologies, Commercial Vehicle Driveline Technologies, Off-Highway Driveline Technologies, and Power Technologies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
